Yamamoto et al., Drug design and discovery 1999
:
Recently, we have reported that FasL is processed to a soluble form by an unknown metalloproteinase at the cell surface and some hydroxamate matrix metalloproteinase ( MMP ) inhibitors inhibit the processing similar to the case observed with TNF-1alpha
Meng et al., Gynecol Oncol 2004
(MAP Kinase Signaling System...) :
Flow cytometry showed that LPA strongly upregulated FasL expression on the OVCAR3 cell surface ( P < 0.01 ), yet in Dov13 cells, LPA significantly upregulated FasL expression only in the presence of the general matrix metalloproteinase ( MMP ) inhibitors GM6001 and MMP inhibitor II ( P < 0.01 )